Last reviewed · How we verify
OmnImmune®
At a glance
| Generic name | OmnImmune® |
|---|---|
| Also known as | fludarabine, cyclophosphamide |
| Sponsor | TC Biopharm |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OmnImmune® CI brief — competitive landscape report
- OmnImmune® updates RSS · CI watch RSS
- TC Biopharm portfolio CI